Sanofi has completed its acquisition of Blueprint Medicines Corporation, enhancing its portfolio with a commercialized medicine and a promising pipeline. This acquisition is expected to bolster Sanofi’s presence among allergists, dermatologists, and immunologists.
The deal includes Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis in the US and EU. Additionally, Sanofi gains elenestinib, an investigational drug for systemic mastocytosis currently under study in a phase 2/3 trial known as HARBOR.
Sanofi also acquired BLU-808, another investigational drug targeting inflammatory diseases. The tender offer for Blueprint shares expired on July 17, 2025, with all conditions satisfied. Following this, Sanofi merged a subsidiary with Blueprint under Delaware law.
The transaction was financed through cash on hand and commercial paper issuances. It is projected to be accretive to business operating income after 2026. All untendered Blueprint shares have been converted into cash payments plus contingent rights based on milestone achievements.
Blueprint stock will no longer trade on NASDAQ as of July 18, 2025.
About Ayvakit: It is the first FDA-approved treatment for systemic mastocytosis in various forms and is available in multiple countries.
Sanofi is committed to developing medicines that improve lives globally and is listed on EURONEXT: SAN and NASDAQ: SNY.
Media inquiries can be directed to Sandrine Guendoul or Evan Berland among others at Sanofi. Investor relations contacts include Thomas Kudsk Larsen and Alizé Kaisserian.
Sanofi warns that forward-looking statements are subject to risks including regulatory actions or market conditions that could affect product success or integration outcomes following acquisitions.
